Literature DB >> 12965907

Antibody responses to Escherichia coli O157 and other lipopolysaccharides in healthy children and adults.

Armando Navarro1, Carlos Eslava, Ulises Hernandez, Jose Luis Navarro-Henze, Magali Aviles, Guadalupe Garcia-de la Torre, Alejandro Cravioto.   

Abstract

In Mexico, diarrheal disease due to different serotypes of Escherichia coli is highly prevalent, with only sporadic isolation of O157 non-H7 strains. This could be due to exposure to the O157 or related E. coli lipopolysaccharide (LPS), such as O7 or O116, at an early age. By using enzyme-linked immunosorbent assay (ELISA) and Western blotting, the present study analyzed 605 serum samples from Mexican adults and infants without clinical symptoms of disease for the presence of antibodies to these three E. coli LPSs. The bactericidal activities of homologous and heterologous rabbit and human serum samples against O7, O116, and O157 E. coli LPSs were also determined. By using a cutoff point of 0.7, it was found by the ELISAs that 28 of 562 (5%) of the serum samples from adolescents and adults and 2 of 43 (5%) of the serum samples from infants less than 1 year of age reacted with the O157 LPS. By using cutoff points between 0.4 and 0.699, the proportion of serum samples from both age groups that reacted with the O157 LPS increased to 20%. Western blotting analysis of selected serum samples that showed an intermediate response against the O157 LPS by the ELISAs showed that 61 of 88 (69%) reacted with the same LPS. A similar result was observed for maternal milk samples. The bactericidal activities of rabbit serum samples against the O7, O116, and O157 LPSs showed that they were positive for both homologous and heterologous antigens. Similar results were observed with the human serum samples. O157 non-H7 strains were identified in only 10% of the E. coli strains isolated from 263 Mexican children with and without diarrhea over the past 15 years. This absence of O157:H7 strains in Mexico may be associated with the presence of antibodies against O157 or related E. coli LPSs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12965907      PMCID: PMC193889          DOI: 10.1128/cdli.10.5.797-801.2003

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  36 in total

1.  The United States National Prospective Hemolytic Uremic Syndrome Study: microbiologic, serologic, clinical, and epidemiologic findings.

Authors:  N Banatvala; P M Griffin; K D Greene; T J Barrett; W F Bibb; J H Green; J G Wells
Journal:  J Infect Dis       Date:  2001-03-01       Impact factor: 5.226

2.  Clinical relevance of a serological cross-reaction between Escherichia coli O157 and Brucella abortus.

Authors:  R H Notenboom; A Borczyk; M A Karmali; L M Duncan
Journal:  Lancet       Date:  1987-09-26       Impact factor: 79.321

3.  Identification of Escherichia coli serotype O157 strains by using a monoclonal antibody.

Authors:  M B Perry; D R Bundle; M A Gidney; H Lior
Journal:  J Clin Microbiol       Date:  1988-11       Impact factor: 5.948

4.  Identification of a serological cross-reaction between Brucella abortus and Escherichia coli 0:157.

Authors:  F A Stuart; M J Corbel
Journal:  Vet Rec       Date:  1982-02-27       Impact factor: 2.695

5.  Structure and serologic properties of O-specific polysaccharide from Citrobacter freundii possessing cross-reactivity with Escherichia coli O157:H7.

Authors:  Y Nishiuchi; M Doe; H Hotta; K Kobayashi
Journal:  FEMS Immunol Med Microbiol       Date:  2000-06

6.  Structure of the O-chain polysaccharide of the phenol-phase soluble lipopolysaccharide of Escherichia coli 0:157:H7.

Authors:  M B Perry; L MacLean; D W Griffith
Journal:  Biochem Cell Biol       Date:  1986-01       Impact factor: 3.626

7.  Verocytotoxin-producing Escherichia coli (VTEC) O157 and other VTEC from human infections in England and Wales: 1995-1998.

Authors:  G A Willshaw; T Cheasty; H R Smith; S J O'Brien; G K Adak
Journal:  J Med Microbiol       Date:  2001-02       Impact factor: 2.472

8.  Diarrhea incidence and farm-related risk factors for Escherichia coli O157:H7 and Campylobacter jejuni antibodies among rural children.

Authors:  Edward A Belongia; Po-Huang Chyou; Robert T Greenlee; Guillermo Perez-Perez; William F Bibb; Edna O DeVries
Journal:  J Infect Dis       Date:  2003-04-09       Impact factor: 5.226

9.  Hemolytic uremic syndrome and diarrhea in Argentine children: the role of Shiga-like toxins.

Authors:  E L Lopez; M Diaz; S Grinstein; S Devoto; F Mendilaharzu; B E Murray; S Ashkenazi; E Rubeglio; M Woloj; M Vasquez
Journal:  J Infect Dis       Date:  1989-09       Impact factor: 5.226

10.  First Shiga toxin-producing Escherichia coli isolate from a patient with hemolytic uremic syndrome, Brazil.

Authors:  Beatriz Ernestina C Guth; Renato Lopes de Souza; Tânia Mara I Vaz; Kinue Irino
Journal:  Emerg Infect Dis       Date:  2002-05       Impact factor: 6.883

View more
  4 in total

Review 1.  Hemolytic uremic syndrome.

Authors:  Caterina Mele; Giuseppe Remuzzi; Marina Noris
Journal:  Semin Immunopathol       Date:  2014-02-14       Impact factor: 9.623

2.  Phage Display Detection of Mimotopes that Are Shared Epitopes of Clinically and Epidemiologically Relevant Enterobacteria.

Authors:  Armando Navarro; Delia Licona-Moreno; Alejandro Monsalvo-Reyes; Ulises Hernández-Chiñas; Carlos A Eslava-Campos
Journal:  Microorganisms       Date:  2020-05-22

3.  Serological evidence of asymptomatic infections during Escherichia coli O104:H4 outbreak in Germany in 2011.

Authors:  Yanina Balabanova; Stefanie Klar; Yvonne Deleré; Hendrik Wilking; Mirko S Faber; Sofie Gillesberg Lassen; Andreas Gilsdorf; Susann Dupke; Martin Nitschke; Friedhelm Sayk; Roland Grunow; Gérard Krause
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

4.  Characterization of Diarrheagenic Strains of Escherichia coli Isolated From Cattle Raised in Three Regions of Mexico.

Authors:  Armando Navarro; Patricia Isidra Cauich-Sánchez; Alejandro Trejo; Alvaro Gutiérrez; Sylvia Paz Díaz; Martha Díaz C; Alejandro Cravioto; Carlos Eslava
Journal:  Front Microbiol       Date:  2018-10-11       Impact factor: 5.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.